Short report: differential evolution of immunoglobulin G1/G3 antibody responses to Plasmodium falciparum MSP1(19) over time in malaria-immune adult Senegalese patients.

Abstract

Abstract. This study examined the evolution of immunoglobulin (Ig) G1 and IgG3 antibodies against the asexual stage Plasmodium falciparum protein, MSP1 19 , before and after a heavy malaria transmission period in clinically immune Senegalese subjects living under different epidemiological conditions. Plasma was tested for antibodies to a yeast-produced, recombinant PfMSP1 19 antigen (the Q-KNG allelic variant) that has previously been demonstrated to react with IgG1, IgG3, or both in the majority of these people. Anti-P. falciparum antibodies of the IgG1 and IgG3 subclasses, previously reported to be associated with protection, were shown to evolve independently one from another after the transmission period in both settings. These results suggest differential regulation of MSP1 19 -specific IgG1 and IgG3. The precise role of these antibody isotypes in maintaining malaria immunity remains to be determined.

Schistosomiasis Coinfection in Children Influences Acquired Immune Response against Plasmodium falciparum Malaria Antigens

“…This difference might be due to different genetic background of these populations and/or to a different intensity of transmission in the studied areas or to environmental factors. Indeed, it was speculated that the differential evolution of plasma IgG1 and IgG3 antibodies resulted from a different catabolism and/or use of these antibodies [32]. Thus, history of malaria exposure, seasonal transmission and the short life of specific IgG3 to MSP1- 19 antigen cannot be excluded to explain the presence or the absence of this specific IgG3 response.…”

Immune effector mechanisms in malaria

“…As mentioned earlier, many merozoite antigens have highly polymorphic regions possibly involved in immune evasion (8,45,46). In addition, antibodies to different variants and parts of the antigens evolve independently (47–49) and may have variable efficacy in protecting against malaria. For example, in Papua New Guinea, only antibodies against the 3D7‐like variants of MSP2 were associated with protection against clinical malaria whereas those against the FC27‐like variants were not (50).…”

Overview of revised measures to prevent malaria transmission by blood transfusion in France

“…However, a systematic deferral period of 4 months after return from an endemic region overcomes this risk (Table 1). Two other situations are more difficult to deal with: the slow development of antibody production after exposure to non‐ P. falciparum , and the low levels and fluctuation of antibody titres in immune individuals [26,27]. Indeed, many immigrants retain some degree of protective immunity to Plasmodiae .…”